EAM
AZN icon

Exome Asset Management’s AstraZeneca AZN Stock Holding History

Exome Asset Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,181
Closed -$3.93M – 75
2025
Q2 		$3.93M Buy
+14,181
New +$1.99M 2.92% 7

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Exome Asset Management's AZN Position: Q1 2026 in Review

Exome Asset Management sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 14,181 shares — an estimated $5.26M sold.

Exome Asset Management first reported a position in AZN in Q1 2025 and held it in 3 quarters. The position peaked at $5.26M in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Exome Asset Management reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Exome Asset Management sold 14,181 AstraZeneca shares in Q1 2026, an estimated $5.26M.
  • Exome Asset Management first reported a position in AstraZeneca in Q1 2025 and held it in 3 quarters.
  • Exome Asset Management's AstraZeneca position peaked at $5.26M in Q4 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.